EVA MARÍA
CIRUELOS GIL
Profesora asociada de Ciencias de la Salud
Harvard University
Cambridge, Estados UnidosPublicaciones en colaboración con investigadores/as de Harvard University (3)
2022
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268
2018
-
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
The Lancet Oncology, Vol. 19, Núm. 1, pp. 127-138
2016
-
Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): The SOFT-EST substudy
Journal of Clinical Oncology, Vol. 34, Núm. 14, pp. 1584-1593